WITHDRAWN: Azacitidine plus low-dose CLAG regimen for relapsed/refractory acute myeloid leukemia: A case report

Cancer Statistics Review 2009-2015. https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 189 August March 2021 19. Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N. Engl. J. Med., 2374, 2209, 10.1056/NEJMoa1516192 Duval, 2010, Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure, J. Clin. Oncol., 28, 3730, 10.1200/JCO.2010.28.8852 Bao, 2018, Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: A prospective cohort study, Clin. Transl. Oncol., 20, 870, 10.1007/s12094-017-1798-8 Muluneh, 2018, A comparison of clofarabine-based (GCLAC) and cladribine-based (CLAG) salvage chemotherapy for relapsed/refractory AML, Clin. Lymphoma Myeloma Leuk., 18, e13, 10.1016/j.clml.2017.09.016 Wang, 2019, Analysis of efficacy and prognostic factors of CLAG treatment in Chinese patients with refractory or relapsed acute myeloid leukemia, Acta Haematol, 141, 43, 10.1159/000493250 Wrzesień-Kuś, 2003, Eur. J. Haematol., 71, 155, 10.1034/j.1600-0609.2003.00122.x Scandura, 2011, Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML, Blood, 118, 1472, 10.1182/blood-2010-11-320093 Qin, 2009, Mechanisms of resistance to 5aza2′deoxycytidine in human cancer cell lines, Blood, 113, 659, 10.1182/blood-2008-02-140038 Füller, 2015, 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation, Int. J. Oncol., 46, 1192, 10.3892/ijo.2014.2792